A new study maps the peripheral immune system of treatment-naive pancreatic ductal adenocarcinoma (PDAC) patients using high-dimensional spectral flow cytometry. By analyzing over 70 immune cell subsets, researchers identified changes in the immune system that distinguish PDAC patients from healthy individuals. This method measures 40+ surface proteins directly, offering detailed insights into functional immune states while preserving fragile clinical samples.
The study found that PDAC triggers a shift from normal immune balance to chronic activation and exhaustion. T cells, especially PD-1+ CD4+ T cells, central memory T cells, and memory regulatory T cells, were expanded, while cytotoxic NK cells, B cells, and some myeloid cells declined. Certain immune patterns correlated with patient outcomes: higher terminal effector CD8+ T cells predicted better survival, while expanded memory CD4+ populations were linked to worse outcomes.
Machine learning identified CD95 and CD45RA as key biomarkers for PDAC, distinguishing it from benign pancreatic inflammation and other conditions. These findings suggest that immune profiling of blood samples could become a non-invasive “liquid biopsy” for early detection, patient stratification, and more precise diagnosis of pancreatic cancer.